Patents by Inventor Bruce J. Baum
Bruce J. Baum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110135614Abstract: The invention provides, a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.Type: ApplicationFiled: January 19, 2011Publication date: June 9, 2011Applicant: THE UNITED STATES OF AMERICA, REPRESENTED BY, DEPA RTMENT OF HEALTHInventors: Yoke Peng Loh, Niamh Cawley, Bruce J. Baum, Christopher R. Snell
-
Patent number: 7888070Abstract: The invention provides a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.Type: GrantFiled: September 6, 2007Date of Patent: February 15, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Yoke Peng Loh, Niamh Cawley, Bruce J. Baum, Christopher R. Snell
-
Patent number: 7618623Abstract: An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5? retroviral LTR nucleic acid sequence, a 3? retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5? LTR or the 3? LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5? LTR and the 3? LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5? and a 3? retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4.Type: GrantFiled: October 19, 2005Date of Patent: November 17, 2009Assignee: The United of States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Changyu Zheng, Brian O'Connell, Bruce J. Baum
-
Publication number: 20090258935Abstract: An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5? retroviral LTR nucleic acid sequence, a 3? retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5? LTR or the 3? LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5? LTR and the 3? LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5? and a 3? retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4.Type: ApplicationFiled: June 19, 2009Publication date: October 15, 2009Inventors: Changyu Zheng, Brian O'Connell, Bruce J. Baum
-
Patent number: 7271150Abstract: The invention provides a growth hormone (GH) in which amino acids within the regulated secretory pathway (RSP) sorting signal have been mutated as well as a GH in which the three-dimensional conformation of the RSP sorting signal has been altered, and a composition comprising an effective amount of such a GH in an excipient.Type: GrantFiled: May 14, 2002Date of Patent: September 18, 2007Assignee: United States of America, Represented by the Secretary, Department of Health and Human ServicesInventors: Yoke Peng Loh, Niamh Cawley, Bruce J. Baum, Christopher R. Snell
-
Patent number: 7226779Abstract: An adenoviral vector is disclosed that includes two adenoviral ITRs, wherein the two adenoviral ITRs flank a packaging signal and a single retroviral LTR operably linked to a nucleic acid sequence of interest, wherein the adenoviral vector does not include a nucleic acid sequence encoding the retroviral structural proteins and wherein the adenoviral vector does not include a second retroviral LTR. In one embodiment, a method for transforming a cell is disclosed. In another embodiment, a method is disclosed for introducing a transgene into a cell with a single viral vector. In a further embodiment, a method is provided for preventing or treating disorder in a subject. A pharmaceutical composition is also provided.Type: GrantFiled: January 25, 2002Date of Patent: June 5, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Changyu Zheng, Bruce J. Baum, Brian C. O'Connell
-
Patent number: 7052904Abstract: An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5? retroviral LTR nucleic acid sequence, a 3? retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5? LTR or the 3? LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5? LTR and the 3? LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5? and a 3? retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4.Type: GrantFiled: January 30, 2001Date of Patent: May 30, 2006Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Changyu Zheng, Brian O'Connell, Bruce J. Baum
-
Publication number: 20040248827Abstract: An adenoviral vector is disclosed that includes two adenoviral ITRs, wherein the two adenoviral ITRs flank a pack-aging signal and a single retroviral LTR operably linked to a nucleic acid sequence of interest, wherein the adenoviral vector does not include a nucleic acid sequence encoding the retroviral structural proteins and wherein the adenoviral vector does not include a second retroviral LTR. In one embodiment, a method for transforming a cell is disclosed. In another embodiment, a method is disclosed for introducing a transgene into a cell with a single viral vector. In a further embodiment, a method is provided for preventing or treating disorder in a subject. A pharmaceutical composition is also provided.Type: ApplicationFiled: July 29, 2003Publication date: December 9, 2004Inventors: Changyu Zheng, Bruce J. Baum
-
Publication number: 20040158046Abstract: Growth hormone (GH) in which the regulated secretory pathway (RSP) sorting signal has been mutated as well as GH in which the three-dimensional conformation of the RSP sorting signal has been altered, a composition comprising an effective amount of such a GH in an excipient, a nucleic acid molecule encoding GH in which the RSP sorting signal has been mutated such the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell as well as a nucleic acid molecule encoding GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell, a vector comprising such a nucleic acid molecule, an isolated host cell comprising such a vector, a method of treating growth hormone deficiency (GHD) and other diseases in a mammal by administering to the mammal the aforementioned composition, nucleic acid or vector or host cells which have been contacted ex vivo with an aforementioned nType: ApplicationFiled: November 14, 2003Publication date: August 12, 2004Inventors: Yoke Peng Loh, Niamh Cawley, Bruce J Baum, Christopher R Snell
-
Publication number: 20040115788Abstract: An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4.Type: ApplicationFiled: July 30, 2002Publication date: June 17, 2004Inventors: Changyu Zheng, Brian O'Connell, Bruce J. Baum
-
Patent number: 6743626Abstract: The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.Type: GrantFiled: August 23, 2001Date of Patent: June 1, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Bruce J. Baum, Kenneth M. Yamada, Edna Cukierman, David Mooney
-
Publication number: 20030031696Abstract: The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.Type: ApplicationFiled: August 23, 2001Publication date: February 13, 2003Inventors: Bruce J. Baum, Kenneth M. Yamada, Edna Cukierman, David Mooney